Entdecken Sie die besten Kosten und Kliniken für der medikamentösen Behandlung von Multipler Sklerose in Republik Korea 2026

South Korea National Health Insurance Service (NHIS) covers multiple sclerosis (MS) medication through a positive listing system based on clinical utility. Patients often qualify for the rare intractable disease designation, reducing standard 30% co-payments to 10% for approved disease-modifying therapies at Joint Commission International-accredited Seoul hospitals.

• Coverage rate: Established disease-modifying therapies typically receive 70% to 90% reimbursement under NHIS protocols.
• High-efficacy drugs: Ocrevus (ocrelizumab) is now reimbursed for relapsing-remitting and secondary progressive MS cases.
• Safety net: The NHIS ceiling system caps annual out-of-pocket costs based on patient income levels.
• Access criteria: Coverage for second-line treatments usually requires documented failure of first-line interferon therapies.

Bookimed Expert Insight: While major centers like Severance Hospital and Seoul National University Hospital offer advanced care, international patients should note that newer monoclonal antibodies often carry a high upfront deductible. Data shows that starting treatment at a university-affiliated clinic facilitates faster access to the rare disease designation, which is crucial for reducing monthly medication costs from $3,000 to approximately $300.

Patient Consensus: Patients emphasize securing the rare intractable disease status early via a neurologist to maximize benefits. They also caution that switching to newer medications can lead to temporary self-pay periods while waiting for hospital committee approvals.

Starting MS treatment in Korea requires a formal diagnosis at a tertiary hospital using the 2017 McDonald Criteria. Patients must undergo brain and spinal MRI with contrast, evoked potentials, and lumbar punctures. Foreigners with existing diagnoses usually require local re-evaluation by Korean neurologists to access the national subsidy system.

• Tertiary centers: Diagnosis occurs at major facilities like Seoul National University Hospital or Severance Hospital.
• Rare disease registration: Physicians must register patients under the V085 code for 90% cost coverage.
• Stepped therapy: Treatment begins with first-line injectables like Interferon-beta or oral Teriflunomide medications.
• Escalation protocol: Moving to high-efficacy drugs like Ocrevus requires documented clinical relapses or MRI activity.

Bookimed Expert Insight: While top-tier facilities like Severance Hospital and SNUH serve millions, wait times for initial MS diagnostics can reach 3 months. Patients seeking faster access to high-efficacy therapies like Ocrelizumab should meticulously document every relapse. High-volume centers prioritize this evidence when petitioning the Health Insurance Review and Assessment Service for second-line drug approvals.

Patient Consensus: Patients emphasize budget planning for 3 to 6 months of out-of-pocket costs if starting high-efficacy treatments before insurance pre-approval. They recommend joining local support groups to access specific appeal templates for better medication coverage.

Multiple sclerosis patients in Korea specifically benefit from the 2024 approval of Ocrevus (ocrelizumab). This therapy targets relapsing and primary progressive MS forms. Major Seoul institutions currently conduct phase 3 clinical trials for BTK inhibitors and advanced mesenchymal stem cell therapies for neuroregeneration.

• Ocrevus availability: Intravenous formulation is available at centers like Seoul National University Hospital.
• BTK inhibitor trials: Active phase 3 studies include Tolebrutinib and Fenebrutinib for secondary progression.
• Stem cell research: Specialized programs at Yonsei Severance Hospital offer autologous and mesenchymal cell treatments.
• Emerging delivery: Subcutaneous Ocrevus injections are undergoing final regulatory review to reduce treatment time.

Bookimed Expert Insight: Korea’s clinical trial landscape is exceptionally centralized in Seoul. Hospitals like Seoul National University Hospital and Severance Hospital manage millions of patients annually. This high volume accelerates recruitment for global trials. Patients often access BTK inhibitors here years before general market release.

Patient Consensus: Patients value the rapid integration of global drugs into the national reimbursement system. Many appreciate the digital efficiency of Seoul’s `smart hospitals` which streamlines long-term monitoring and follow-up care.

Rediagnosis in the Republic of Korea is generally required to access local treatment and prescription medication. While Korean neurologists recognize the global McDonald criteria, major academic centers in Seoul typically perform independent evaluations including new MRIs and lumbar punctures to establish a clinical baseline and satisfy strict national health insurance protocols.

• Diagnostic verification: Major hospitals usually repeat MRIs and laboratory tests to ensure local clinical accuracy.
• Medication access: Korean health insurance requires domestic confirmation before approving high-cost disease-modifying therapies like Ocrevus.
• Timeline impact: The internal rediagnosis process often adds 2 to 6 weeks before starting treatment.
• Documentation needs: Patients must provide original imaging CDs and raw lab data, not just summaries.

Bookimed Expert Insight: Data from leading Seoul institutions like Severance Hospital and Seoul National University Hospital shows a strict adherence to digitalized internal records. While these hospitals are world-class—with Severance managing 1.6 million outpatients annually—they rarely skip local diagnostics. To save time, choose a digital-first clinic like SNUBH which uses AI imaging to potentially speed up the comparison of your old scans with new results.

Patient Consensus: Patients report that while translating foreign neurology reports is helpful, major Seoul hospitals still insist on redoing tests. Many recommend contacting the hospital before traveling to confirm if they will accept original digital imaging files.